PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,063,211 | -49.4% | 914,707 | -34.0% | 0.01% | -46.7% |
| Q2 2023 | $55,492,303 | -2.8% | 1,384,884 | -1.0% | 0.02% | -6.2% |
| Q1 2023 | $57,072,215 | +8.6% | 1,398,486 | +2.8% | 0.02% | +6.7% |
| Q4 2022 | $52,534,040 | -13.6% | 1,360,633 | +19.0% | 0.02% | -25.0% |
| Q3 2022 | $60,795,000 | -4.2% | 1,142,969 | +5.0% | 0.02% | +5.3% |
| Q2 2022 | $63,474,000 | +123.1% | 1,088,741 | +192.1% | 0.02% | +171.4% |
| Q1 2022 | $28,446,000 | +0.3% | 372,723 | -20.9% | 0.01% | 0.0% |
| Q4 2021 | $28,362,000 | -6.1% | 471,366 | -12.6% | 0.01% | -12.5% |
| Q3 2021 | $30,212,000 | +9.6% | 539,504 | +18.8% | 0.01% | +14.3% |
| Q2 2021 | $27,554,000 | -29.1% | 454,091 | -18.1% | 0.01% | -30.0% |
| Q1 2021 | $38,878,000 | +7.5% | 554,690 | -8.2% | 0.01% | -9.1% |
| Q4 2020 | $36,177,000 | -0.5% | 604,555 | -0.1% | 0.01% | -8.3% |
| Q3 2020 | $36,374,000 | +3.2% | 605,036 | -10.0% | 0.01% | -7.7% |
| Q2 2020 | $35,262,000 | +134.3% | 672,044 | +49.7% | 0.01% | +116.7% |
| Q1 2020 | $15,052,000 | -45.6% | 448,907 | -26.5% | 0.01% | -33.3% |
| Q4 2019 | $27,649,000 | +215.8% | 610,352 | +165.5% | 0.01% | +350.0% |
| Q3 2019 | $8,754,000 | -35.2% | 229,930 | -26.0% | 0.00% | -33.3% |
| Q2 2019 | $13,516,000 | -10.6% | 310,779 | -21.7% | 0.00% | -40.0% |
| Q1 2019 | $15,116,000 | -5.8% | 397,141 | +6.5% | 0.01% | -16.7% |
| Q4 2018 | $16,044,000 | -22.7% | 372,916 | -11.6% | 0.01% | -14.3% |
| Q3 2018 | $20,745,000 | +2052.0% | 422,068 | +1303.3% | 0.01% | – |
| Q2 2018 | $964,000 | -80.8% | 30,077 | -81.3% | 0.00% | -100.0% |
| Q1 2018 | $5,011,000 | -83.2% | 160,852 | -75.3% | 0.00% | -81.8% |
| Q4 2017 | $29,747,000 | +18.9% | 651,644 | -2.2% | 0.01% | +22.2% |
| Q3 2017 | $25,015,000 | -21.9% | 666,176 | -0.8% | 0.01% | -10.0% |
| Q2 2017 | $32,017,000 | +3.1% | 671,231 | -1.4% | 0.01% | 0.0% |
| Q1 2017 | $31,050,000 | +42.7% | 680,903 | +1.1% | 0.01% | +42.9% |
| Q4 2016 | $21,761,000 | +17.7% | 673,737 | +24.7% | 0.01% | +16.7% |
| Q3 2016 | $18,492,000 | +1.7% | 540,405 | +0.3% | 0.01% | -14.3% |
| Q2 2016 | $18,176,000 | -57.8% | 538,856 | -33.7% | 0.01% | -61.1% |
| Q1 2016 | $43,087,000 | -36.3% | 813,258 | -7.7% | 0.02% | -33.3% |
| Q4 2015 | $67,665,000 | +80.3% | 881,174 | -3.5% | 0.03% | +68.8% |
| Q3 2015 | $37,536,000 | -61.5% | 913,279 | -33.8% | 0.02% | -57.9% |
| Q2 2015 | $97,529,000 | -6.2% | 1,379,086 | +17.8% | 0.04% | -5.0% |
| Q1 2015 | $104,007,000 | -2.6% | 1,170,587 | -2.8% | 0.04% | -2.4% |
| Q4 2014 | $106,737,000 | +49.3% | 1,203,886 | +63.2% | 0.04% | +41.4% |
| Q3 2014 | $71,495,000 | +24.0% | 737,662 | +17.6% | 0.03% | +26.1% |
| Q2 2014 | $57,635,000 | +546.8% | 627,414 | +392.8% | 0.02% | +475.0% |
| Q1 2014 | $8,911,000 | +204.1% | 127,322 | +149.8% | 0.00% | +300.0% |
| Q4 2013 | $2,930,000 | +0.1% | 50,969 | -16.3% | 0.00% | 0.0% |
| Q3 2013 | $2,928,000 | +478.7% | 60,914 | +248.8% | 0.00% | – |
| Q2 2013 | $506,000 | – | 17,464 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |